Cachectin (tumor necrosis factor) is a powerful macrophage hormone released during infection, which circulates in blood to produce diverse effects in the organism. We examined the effect of cachectin on release of anterior pituitary hormones from either hemipituitaries or dispersed pituitary cells incubated in vitro. The action of cachectin on dispersed cells was demonstrable only after 2 hr of incubation. With this incubation time, the protein produced a dose-related stimulation of release of adrenocorticotropin (ACTH), growth hormone (GH), and thyrotropin (TSH), but not of prolactin (Prl), from both hemipituitaries and dispersed cells. The doses required for stimulation were low in the case of hemipituitaries, usually of the order of 10-12 M, whereas they were higher by one or two orders of magnitude with the dispersed pituitary cells. This may be related either to loss of receptors for the protein during the dispersion procedure or to the fact that in the hemipituitary system cell interactions are facilitated because the cells are dose to each other. In the dispersed cell system cachectin evoked a dose-related decrease in cyclic AMP content. Incubation with somatostatin lowered the cyclic AMP content of the cells and depressed GH output without altering output of TSH or Prl. When somatostatin and cachectin were incubated together with the cells, the suppression ofcyclic AMP production was abolished; TSH and Prl release were stimulated, but the action of cachectin to stimulate GH release was blocked. The stimulation of Prl release by cachectin in the presence of somatostatin may be related to the elevation of cyclic AMP, a known stimulator of Prl release. The cyclooxygenase inhibitor indomethacin nearly completely blocked the stimulatory effect of cachectin on release of GH and TSH from dispersed pituitary cells but had only a slight and nonsignificant attenuating effect on its ACTH-releasing action. These results suggest that at least part of the stimulatory action of the peptide on pituitary hormone release is brought about by prostaglandins. The failure of indomethacin to block the release of ACTH induced by cachectin suggests that other mechanisms may be involved in the release of ACTH induced by this peptide. Since the concentrations of cachectin required to stimulate pituitary hormone release are similar to those that are encountered in plasma during infection, it is likely that this direct pituitary action has pathophysiological significance.
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In recent years, it has become apparent that there are important interactions between the immune system on the one hand and the central nervous and endocrine systems on the other. This has led to the development of a new term, "neuroimmunomodulation" (1) . It is now established that interleukin 1, a monokine released from monocytes on exposure to bacterial endotoxins, has important effects to alter pituitary hormone release by hypothalamic (2-6) and possibly direct pituitary (7) actions.
Recently, an additional monokine has been characterized. This is the macrophage hormone cachectin (8) , which is identical to tumor necrosis factor (TNF) (9, 10) . Cachectin is also released in response to infection, and the most effective promoter of its release is bacterial endotoxin, a lipopolysaccharide (11) . Exposure of macrophages to endotoxin in vitro results in synthesis of cachectin mRNA and protein (12) .
Cachectin is released from macrophages and circulates in blood to produce many effects in the organism. Low concentrations can activate phagocytosis and may play a beneficial role in combating infection; however, overwhelming infection results in massive stimulation by endotoxin and a discharge of large quantities of the hormone into the circulation. It acts on endothelial cells to release interleukin 1 (13, 14) . Both interleukin 1 and cachectin itself act on temperature-regulating centers to induce fever (8) . There are many other effects of cachectin that can induce the "endotoxic shock syndrome" produced by bacterial lipopolysaccharides (8) .
Hormonal changes have been demonstrated after intravenous injection of cachectin in dogs; these include increases in circulating epinephrine, norepinephrine, cortisol, and glucagon (15) . Therefore, cachectin can activate adrenocorticotropin (ACTH) secretion; however, there have been no studies to determine the mechanism by which this effect takes place. It could be a result of afferent impulses impinging on the hypothalamus from the multitudinous peripheral effects of the hormone or as the result of effects on the areas regulating body temperature, which in turn cause release of corticotropin-releasing factor (CRF) and/or vasopressin that directly stimulate the pituitary (16) (17) (18) $To whom reprint requests should be addressed.
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In experiments with incubation of dispersed pituitary cells, anterior pituitaries were minced with a razor blade and then enzymatically dispersed to a single-cell suspension in 0.1% trypsin (Difco, 1:250)/1% bovine serum albumin (Sigma) in minimal essential medium (GIBCO) without calcium. The cells were recovered from the trypsin solution by centrifugation (800 x g, 10 min) and suspended in medium 199 (GIBCO) containing 10% horse serum buffered at pH 7.2 with 20 mM Hepes (Sigma) and were cultured overnight. The following morning medium containing 10% horse serum was changed to medium containing 1% bovine serum albumin, and the cells were incubated at 370C for 30 min. Thereafter the cells were centrifuged, and the medium was discarded. The cell pellet was resuspended in the experimental medium (medium 199/1% bovine serum albumin) in the presence or absence of test compounds and incubated at 370C for 2 hr (19) . After incubation the medium was removed and kept at -20'C until hormone measurement by radioimmunoassay. Indomethacin (Merck Sharp & Dohme) and somatostatin (Sigma) were used in final dilutions of 10 AM and 10 nM, respectively. Recombinant human cachectin, with a specific activity of 108 units/mg of protein in the L-929 bioassay system, was used in these experiments. The lipopolysaccharide content of the preparation was <0.1 ng/mg of protein.
To determine their cyclic AMP content, cells were precipitated with cold 6% trichloroacetic acid and frozen and thawed. Residual trichloroacetic acid was extracted with water-saturated diethyl ether (3 vol, three times). The aqueous fraction, containing cyclic AMP, was dried under nitrogen. The resultant residue was dissolved in 50 mM sodium acetate buffer, pH 6.2. Cyclic AMP was determined by radioimmunoassay of the acetylated samples (20) . Antibody to cyclic AMP was purchased from Miles Laboratories, and 3', 5'-cyclic AMP for standards and iodination was obtained from Sigma.
In other experiments the anterior pituitaries were cut in half longitudinally and incubated for 1 hr in Krebs-Ringer bicarbonate buffer. Fresh medium containing either the diluent or various doses of cachectin was then added, and the incubation was continued for 2 hr (21 Stimulatory Effect of Cachectin on the Release of ACTH, GH, and TSH from Hemipituitaries Incubated in Vitro. The protein had a significant stimulatory effect on the release of ACTH, with a bell-shaped dose-response curve and the maximal significant response occurring at 10-10 M (Fig. 1 ).
This contrasted with the failure of the peptide consistently to alter Prl release significantly from the same hemipituitaries. In two of four experiments there was significant stimulation. The peptide also significantly stimulated the release of GH from the same hemipituitaries; the response was doserelated, with a bell-shaped dose-response curve as in the case of ACTH. However, in this case the maximal effect occurred at a lower concentration, 10-12 M. The dose-response relationship for TSH release was similar to that for GH except that the peak was much sharper and there was no clear stimulation except at the dose of 10-12 M (data not shown).
Effect and Mechanism of Releasing Action of Cachectin on Dispersed Anterior Pituitary Cells. As in the case of the hemipituitaries, cachectin induced a dose-related and significant stimulation of ACTH release, with the maximal effect occurring at the highest concentration tested (10-9 M) (Fig.   2) . As in the case of the hemipituitaries the effects on ACTH release contrasted with the inconstant stimulation of Prl release. Again, agreeing with the results with hemipituitaries, TSH release was stimulated in a dose-related fashion, with highly significant stimulation at both 10-10 and 10-9 M. These stimulations were not distinguishable from each other statistically. Similarly, there was a dose-related stimulation of GH release, which achieved statistical significance at 10-10 M.
However, in this case there was a tendency for a bell-shaped curve, such that the stimulation was less at 10-9 M and no longer significantly above basal values (data not shown). It is noteworthy that the concentrations required to stimulate the release of the three pituitary hormones in the dispersed cell system were greater than those needed with hemipituitaries.
To determine the mechanism of the stimulatory effects, we compared the responses in the presence and absence of somatostatin (10 nM). As might be expected, somatostatin suppressed basal GH release and blocked the stimulatory effect of 10-10 M cachectin (Fig. 3) . With TSH. Not only was basal and stimulated TSH release not significantly affected by somatostatin, but TSH release was again highly significantly stimulated by 10-10 M cachectin. The addition of 10-10 M cachectin significantly lowered (P < 0.025) the cyclic AMP concentration in the cells at the end of the experiment (Fig. 3) . A similar lowering was achieved by somatostatin and in this instance the action of cachectin was reversed; it raised cyclic AMP concentrations back to control values. In another experiment cachectin had a doserelated action to lower cyclic AMP with a significant effect at 10-9 M and an even greater effect at 5 x 10-9 M (Fig. 4) .
To determine if there might be any role of prostaglandins in the action of cachectin to alter pituitary hormone release, indomethacin (10 ,uM) , an inhibitor of cyclooxygenase, was added to the system during the time of incubation with cachectin. Indomethacin completely inhibited the significant stimulation of GH and TSH release observed in control incubations with cachectin, without significantly altering stimulation of ACTH release (Fig. 5) .
The various doses of cachectin had no effect on the viability of the dispersed cells as shown by dye exclusion studies.
DISCUSSION
These results demonstrate that in vitro cachectin powerfully stimulates the release of most anterior pituitary hormones except Prl either from hemipituitaries or in dispersed cell preparations. There was consistent stimulation of the release of ACTH, GH, and TSH but inconsistent stimulation of release of Prl at doses which significantly stimulated the release of the other hormones. In general the dose-response curves were bell-shaped, as has been previously reported for other effects of peptides such as the stimulation of TSH release by vasopressin (22, 23) . Surprisingly, a stimulatory action on Prl was revealed when the dispersed cells were incubated in the presence of somatostatin, which by itself failed to alter Prl release. Somatostatin reduced the basal output of GH and blocked the stimulatory action of cachectin. It had no effect on basal or stimulated release of TSH.
The responses occurred at low concentrations of cachectin, similar to those that circulate after injection of bacterial endotoxins or in infection in diverse species (24) (25) (26) , which suggests that these actions may be of importance in vivo. Interestingly, these effects required incubation with the peptide for over 1 hr and were detectable at 2 hr. Thus, the pituitary actions may be of significance only after prolonged elevation of circulating cachectin, as would be likely to occur in infections. To determine the physiologic significance of these effects will require passive immunization studies utilizing antibodies directed against cachectin or specific antagonists of its action.
In initial attempts to determine the mechanism of the stimulatory actions of cachectin, cyclic AMP was determined in the cells at the end of the incubation and a dose-related lowering of cyclic AMP concentrations was found. Reversal ofthis lowering action by somatostatin was also accompanied by stimulation of release of Prl. Somatostatin itself lowered cyclic AMP, as might be expected from prior results (27) . It acts on a variety of cells in the pituitary gland to lower cyclic AMP, and the lowering is accompanied by decreased release not only of GH but also, at least at high doses, of Prl and TSH (27) . The stimulatory action of cachectin on Prl release in the presence of somatostatin may be brought about by an elevation of cyclic AMP, which may have occurred in the lactotrophs, but only in the presence of somatostatin plus cachectin. Therefore, elevation of cyclic AMP may be a factor in promoting Prl release in response to cachectin. Indeed, exogenous cyclic AMP can stimulate Prl release (28) . Although indomethacin did not alter basal hormone release, it blocked the releasing action of cachectin on both GH and TSH. These results suggest that cachectin interaction with receptors on pituitary cells leads to activation of prostaglandin synthetase, which generates the release of prostaglandins that in turn stimulate release of GH and TSH. Earlier experiments have shown that prostaglandins can indeed release these various pituitary hormones by direct action in vitro (29) . Thus, the results support the hypothesis that the releasing action of cachectin is mediated at least in part by prostaglandins. Recently, experiments have been reported which indicate that cachectin can stimulate endogenous production of prostaglandin E2 by macrophages (30) and that this action is also blocked by the cyclooxygenase inhibitor indomethacin, which suppresses the metabolic activation of macrophages. It appears that the action of cachectin on pituitary cells may be similar to that on macrophages. The failure of indomethacin to block the ACTH-releasing action of cachectin is puzzling and suggests a role for other intracellular mediators in this action.
In the meantime, we have recently carried out in vivo experiments in which various doses of cachectin were injected into the third ventricle of conscious rats (31) . In these in vivo experiments slight elevations of ACTH, GH, and Prl in plasma were obtained. Whether these in vivo effects are due to actions at the hypothalamic or pituitary level is yet to be ascertained; however, the present experiments clearly establish effects of cachectin on the pituitary.
